FOLFIRI 方案单用及与贝伐珠单抗联用一线治疗 IV 期直肠癌临床疗效比较

目的：观察 FOLFIRI 方案单用及与贝伐珠单抗联用一线治疗 IV 期直肠癌临床疗效和安全性。方法：研究对象选取我院2012年4月－2013年4月收治 IV 期直肠癌患者90例，采用随机抽样方法分为 A 组（45例）和 B 组（45例），分别采用 FOLFIRI 方案单用和与贝伐珠单抗联用治疗。比较两组患者临床近期疗效，生存率，治疗前后 KPS 评分及 III －IV 级药物不良反应发生率等。结果：B 组患者临床近期疗效显著优于A 组，差异有统计学意义（P ＜0．05）。B 组患者生存率显著高于 A 组，差异有统计学意义（P ＜0．05）。B 组患者治疗后 KPS 评分显著高于 A 组以及治疗前，差异有统计学意义（P ＜0．05）。两组患者 III －IV 级不良反应发生率比较差异无统计学意义（P ＞0．05）。结论：相较于 FOLFIRI 方案单用治疗，FOLFIRI 方案与贝伐珠单抗联用一线治疗 IV 期直肠癌可有效延缓病情进展，提高远期生存率及生活质量，且无严重药物不良反应。

Comparison of clinical efficacy between FOLFIRI regimen used alone and combined with bevacizumab in first -line treatment of patients with rectal cancer in IV stage

Objective:To investigate clinical effects and safety of FOLFIRI regimen used alone and combined withbevacizumab in first -line treatment of patients with rectal cancer in IV stage.Methods:All 90 patients with rectalcancer in IV stage were chosen in the period from April 2012 to April 2013 in our hospital and randomly divided intotwo groups including A group (45 patients)with FOLFIRI regimen used alone and B group (45 patients)with FOL FIRI regimen combined with bevacizumab.Results:The clinical efficacy of short -term of group B was significantlybetter than group A(P <0.05).The survival rate of B group was significantly higher than A group(P <0.05).TheKPS score of B group after treatment was significant better than A group and before treatment(P <0.05).There wasno significant difference in drug side effects between two groups (P >0.05).Conclusion:Compared with FOLFIRIregimen used alone,FOLFIRI regimen combined with bevacizumab in first -line treatment of patients with rectalcancer in IV stage can efficiently delay the progress of disease,improve the survival rate and quality of life,without se rious side effects.